KRAS and non-small cell lung carcinoma: A steady “workhorse” of these efforts was the NSCLC model established by Tuveson, Jacks, and Berns: the combination of conditional deletion of the whole coding sequence of the tumor suppressor Trp53 (Trp53fl/fl) in combination with the conditional expression of the oncogenic variant of KRas (KRasG12D KRaslsl–G12D/wt) (Jackson et al., 2005; DuPage et al., 2009).